^{31T0400} Influence of key polymer attributes, manufacturing conditions and sintering on abuse deterrence of physical barrier type abuse deterrent formulations (ADF)

Heather Boyce¹, Vivek Dave², Myke Scoggins³, Dan Smith⁴, Steve Byrn⁴, Bhawana Saluja⁵, Wen Qu⁶, Vadim J. Gurvich⁷, Stephen W. Hoag¹ 1. University Maryland Baltimore, School of Pharmacy | 2. St John Fischer, Wegmans School of Pharmacy | 3. Micromeritics | 4. Purdue University 5. Office of Clinical Pharmacology, U.S. Food and Drug Administration | 6. Office of Pharmaceutical Quality, U.S. Food and Drug Administration | 7. NIPTE


Purpose

When sintering is used to treat tablet formulations containing polyethylene oxide (PEO), the polymer particles are able to form stronger bonds thereby increase tablet tensile strength. This increase in strength can make it more difficult for an abuser to break, chew, or grind opioid tablets. A mechanistic study was implemented to understand the key sintering factors that influence tensile strength.

Methods


The ADF tablets were composed of PEO and inert filler dicalcium phosphate anhydrous. 10 mm flat faced tooling was used to compress the tablets on a Beta Manesty press.

- Sintering Variables □ Tablet solid fraction (SF) [0.73, and 0.8] [0.77 used for SF PEO] □ PEO particle size [superfine & standard] standard size PEO taken directly from the container or SF PEO obtained from the sieve fraction of 150 to 250 µm was used. □ sintering time @ 80°C [0, 0.167, 0.5, 1, 3, 9 and 15 hr] Concentration of PEO
- [30, 50, 70 wt%]



- Tablet Characterization Techniques
- □ SEM
- □ DSC (crystallinity)
- Pore diameter by Mercury porosimetry
- BET surface area
- □ Hardness Tester for tensile strength

Results







Disclaimer: This poster reflects the views of the authors and should not be construed to represent FDA's views or policies

곗 aads

Conclusions **Properties of PEO that lead to abuse deterrence** When sintering PEO with dicalcium phosphate anhydrous at 80°C, the □ Low Glass Transition: -70°C microstructural changes occur within □ Linear backbone structure for hour of sintering. highly ordered crystal structure The tensile strength increases only when Highly crystallinity the microstructure is changing; sintering >90% provides overall strength between 1 to 15 hr does not yield any Amorphous components allow significant increases in tensile strength. for toughness or exhibits ductile The decrease in crystallinity results in behavior more amorphous regions in the PEO lattice which could increase the ductility of HTO. ∑он the dosage form. A high initial solid fraction yields a more **Tensile Strength: Abuse Deterrent Response** controlled sintering process. □ Fractional density at low PEO content (high m value) **R**eferences □ A smaller particle size distribution (SF PEO) 1. German RM. Sintering Theory and Practice. New York, NY: John Wiley and As the amount of PEO in the dosage form increases, the tensile strength Sons, Inc.; 1996. becomes less dependent on solid fraction of the dosage form as indicated 2. McKenna WH, Mannion RO, O'Donnell by high m values. The sintering time was found not to significantly EP, Huag HH, inventors; Purdue Pharma L.P., increase the tensile strength after 1 hr of sintering. Significant tensile assignee. Tamper Resistant Dosage Forms. strength gains were only realized during first 1 hr of sintering in which United States patent 8808741. 2014 significant tablet microstructure changes occurred. Finally, the super fine 3. German RM. Surface area reduction PEO demonstrated a huge increase in tensile strength in the non-sintered during isothermal sintering. Journal of state. The sintered tablets made with superfine PEO were unable to be American Ceramic Society. broken under compressive stress and 300 N. 1976;59(9/10):379-83 $Log[\sigma] = Log[\sigma_0 K] + mLog[V_s]$ **Acknowledgements** 60 rength S0 31±2 We are grateful to the National Institute for ੱਦ 40 Str Pharmaceutical Technology and Education -0-70HSF (NIPTE) and the U.S. Food and Drug 20 Administration (FDA) for providing funds for this research. This study was funded by the 10 FDA contract to NIPTE # HHSF223201301189P. We would also like 0.64 0.69 0.74 Fractional Density, Vs to thank Micromeritics Instrument Company for the generous donation of analytical 70% Fit 30% services to conduct the mercury porosimetry PEO 50% PEO PEO Parameters and surface area measurements. We would also like to thank DOW chemical for their 8 10 15 m 0 Sinter Time (min) generous donation of POLYOX. 0.84 0.99 **R2** 0.79